That is a very good point.
I did re-read the VALOUR paper and looked at how they've accounted for it. In Fig 1 of the paper below, drop outs were actually included in the end point analysis. So the 15th percentile in that trial should still be comparable to ours.
http://jco.ascopubs.org/content/30/28/3499.full.pdf
Edit: I meant assuming we've handled adverse events the same way they did (i.e. counting it as one of the 350 events)
Something funny happened ....., page-19
Add TSN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable